Supercharged immune cells aim to beat back tough leukemia
NCT ID NCT02782546
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 25 times
Summary
This study tests whether giving patients with hard-to-treat acute myeloid leukemia (AML) specially trained immune cells (memory-like NK cells) after a half-matched donor stem cell transplant can keep the cancer away longer. About 60 adults whose leukemia did not respond to standard chemotherapy or came back will receive this cell therapy. The goal is to see if more patients can stay cancer-free for at least 100 days after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.